New pill aims to quiet the constant worry of anxiety disorder

NCT ID NCT05970510

Completed Symptom relief Sponsor: Luye Pharma Group Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a new medication, toludesvenlafaxine, can safely reduce anxiety symptoms in adults with generalized anxiety disorder. Participants receive either a low dose, a high dose, or a placebo pill daily for 8 weeks. The main goal is to see if the drug lowers anxiety scores more than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toludesvenlafaxine hydrochloride
What this could lead to: If successful, this could provide a new medication option for people with generalized anxiety disorder, helping reduce their anxiety symptoms.
What could go wrong: This is a phase 3 trial, but results may not show a meaningful benefit over placebo. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED ANXIETY DISORDER

Contacts and locations

Show contact details

Locations

Peking University Sixth Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.